Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
Yahoo3 gün önceTECH
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Fiscal 2026 highlights:Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targetsMarket-based Scope 1 and 2 emissions reduced 49% year-over-yearMore than half of the
Benzinga3 gün önceTECH
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.
Yahoo3 gün önceTECH
1 Surging Stock for Long-Term Investors and 2 That Underwhelm
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Yahoo9 gün önceTECH
1 Profitable Stock to Own for Decades and 2 We Turn Down
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Yahoo11 gün önceTECH
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Yahoo14 gün önceTECH
Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.
Yahoo17 gün önceTECH
3 High-Flying Stocks We Approach with Caution
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Yahoo17 gün önceTECH
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
Benzinga21 gün önceTECH
Bio-Techne Corrects Dividend Announcement
Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged.
Yahoo22 gün önceTECH
Techne (TECH) Q4 Earnings Meet Estimates
Techne (TECH) delivered earnings and revenue surprises of 0.00% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo23 gün önceTECH
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ consensus estimates.
Yahoo23 gün önceTECH
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.
Yahoo23 gün önceTECH
Bio-Techne Declares Dividend
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Yahoo23 gün önceTECH
Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 1.89 percent decrease over earnings of $0.53 per share from the same period last year. The
Benzinga23 gün önceTECH
Is Bio-Techne (TECH) Above Fair Value After A 44% Return?
Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain. Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price. Expectations around Bio-Techne's ability to grow revenue and sustain healthy cash flows...
Yahoo27 gün önceTECH